Lyme Disease Antibody with Reflex to Immunoassay (IgG, IgM)
Also known as: MTTT-2, Borrelia VlsE1 pepC10, B. burgdorferi Ab, Lyme Early, Borrelia ELISA
Use
This test employs the CDC-recommended modified two-tier testing (MTTT) algorithm for Lyme disease serologic diagnosis; it begins with a first-tier immunoassay measuring combined IgG and IgM antibodies to Borrelia burgdorferi, and reflexes to separate IgG and IgM immunoassays if the initial result is positive or equivocal, facilitating earlier detection of Lyme disease within the first 30 days of infection. It cannot distinguish reinfection from prior exposure and cannot prove cure; serologic responses may persist long after infection resolution. It follows CDC guidelines and FDA-cleared assay indications. Quest offers this test in parallel with the traditional standard two-tier test (STTT) to improve early Lyme detection. ([questdiagnostics.com](https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq224?utm_source=openai))
Special Instructions
Not provided.
Limitations
Serologic testing may yield false-negative results during early infection before antibodies develop, and false-positive results may occur due to cross-reactivity with other conditions, including other spirochetal diseases, viral infections such as EBV or CMV, or autoimmune disorders. Antibodies may persist for months or years after infection, so this test cannot confirm cure, nor can it determine reinfection versus past exposure. ([questdiagnostics.com](https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq224?utm_source=openai))
Methodology
Immunoassay
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Not provided.
Other tests from different labs that may be relevant